Investors & Media

Press Releases

View all press releases »

Webcast Alert: Isis Pharmaceuticals, Inc. Announces Its Fourth Quarter Financial Results on the Web;

February 4, 2002 at 12:00 AM EST

Live and Archived Conference Call Notification

CARLSBAD, Calif., Feb. 4 /PRNewswire-FirstCall/ -- In conjunction with Isis Pharmaceuticals, Inc.'s (Nasdaq: ISIP) Fourth Quarter Financial Results, you are invited to listen to its conference call that will be broadcast live over the Internet on Feb. 7, 2002 at 11:00 a.m. Eastern Time.

    What:     Isis Pharmaceuticals, Inc. to Discuss 4th Quarter 2001 Financial

When: Feb. 7, 2002 at 11:00 a.m. Eastern Time

Where: or

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Ruth Mealey --- 760-603-2331 ---

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 products in its development pipeline, with two in late-stage development and seven in Phase II human clinical trials. LY900003 (ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of nearly 900 issued patents worldwide. Isis' GeneTrove™ division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services and access to an extensive gene function database. Ibis Therapeutics™ is a division focused on the discovery of small molecule drugs that bind to RNA. Additional information about Isis is available at .

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to ).

SOURCE Isis Pharmaceuticals, Inc.
Web site: http: //
CONTACT: Ruth Mealey of Isis Pharmaceuticals, Inc., +1-760-603-2331,
Audio: http: //